Nepafenac


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : Ophth Post-op ocular inflammation w/ cataract surgery Instillation starts 1 day before surgery, the day of surgery, and through the 1st 2 wk post-op. Instill 1 drop into the affected eye tid (0.1% susp) or once daily w/ an additional drop 30-120 min before surgery (0.3% susp). Macular oedema risk reduction following cataract surgery in diabetic patients Instillation starts 1 day before the surgery, the day of surgery, and up to 60 days post-op. As 0.1% susp: Instill 1 drop into the affected eye tid; w/ an additional drop 30-120 min before surgery.
Dosage Details
Ophthalmic
Postoperative ocular inflammation
Adult: Instillation starts 1 day before the cataract surgery, the day of surgery, and through the 1st 2 wk post-op period. As 0.1% susp: Instill 1 drop into the affected eye(s) tid. As 0.3% susp: Instill 1 drop into the affected eye(s) once daily; w/ an additional drop 30-120 min before surgery.
Child: ≥10 yr Same as adult dose.

Ophthalmic
Macular oedema risk reduction following cataract surgery in diabetic patients
Adult: Instillation starts 1 day before the cataract surgery, the day of surgery, and up to 60 days post-op period. As 0.1% susp: Instill 1 drop into the affected eye(s) tid; w/ an additional drop 30-120 min before surgery.
Contraindications
Hypersensitivity to nepafenac or other NSAIDs.
Special Precautions
Patient w/ complicated ocular surgeries, corneal denervation, corneal epithelial defects, DM, ocular surface disease (e.g. dry eye syndrome), rheumatoid arthritis, repeat ocular surgeries w/in a short period of time, predisposition to bleeding. Pregnancy and lactation.
Adverse Reactions
Significant: Punctate keratitis.
Nervous: Headache.
CV: HTN.
GI: Nausea, vomiting.
Resp: Sinusitis.
Ophthalmologic: Capsular opacity, decreased visual acuity, foreign body sensation, increased IOP, sticky sensation, conjunctival/corneal oedema, dry eye, lid margin crusting, discomfort, hyperaemia, ocular pain and pruritus, photophobia, tearing, vitreous detachment.
Patient Counseling Information
Avoid wearing contact lens during treatment. This drug may cause transient blurring of vision, if affected, do not drive or operate machinery.
Drug Interactions
Increased potential for healing problems w/ ophth corticosteroids.
Action
Description: Nepafenac is an NSAID and analgesic prodrug which penetrates the cornea after ocular application. It is converted by ocular hydrolases to amfenac, an active metabolite that decreases the production of prostaglandin by inhibiting prostaglandin H synthase or cyclooxygenase enzyme.
Pharmacokinetics:
Distribution: Plasma protein binding: 95.4%, primarily to albumin.
Metabolism: Undergoes rapid bioactivation by intraocular hydrolases to amfenac, an active metabolite.
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store between 2-25°C. Protect from light.
ATC Classification
S01BC10 - nepafenac ; Belongs to the class of non-steroidal antiinflammatory agents. Used in the treatment of inflammation of the eye.
Disclaimer: This information is independently developed by MIMS based on Nepafenac from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in